Digestive System Diseases

633 trials 301 recruiting

Filter these 633 trials by phase, country and sponsor.

Open in Search →

Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Mult… Recruiting

2024-520090-12-00 Esophageal cancer 1 2026-05-01
A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter S… Recruiting

2025-524733-11-00 Unresectable Locally Advanced Pancreatic Cancer 9 2026-04-22
Guselkumab intervention and diet evaluation for pouchitis Recruiting

2025-521683-35-00 Pouchitis 6 2026-04-21
A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's dise… Recruiting

2024-518898-34-00 Anal or recto-cutaneous or recto-vaginal Crohn-related 10 2026-04-21
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting

2025-522046-42-00 Colonic disease 5 2026-03-24
Safety of rotigotine in patients with autosomal dominant polycystic kidney disease - ETERNAL-PKD Recruiting

2024-515734-32-00 Kidney Disease 4 2026-03-20
Adjuvant radioligand therapy in neuroendocrine tumors Recruiting

2024-518236-36-00 Locoregionally restricted (stage III) small intestinal 5 2026-03-12
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting

2024-520128-27-00 colorectal adenocarcinoma 4 2026-03-04
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting

2024-517766-41-00 Patients with metastatic pancreatic ductal adenocarcino 4 2026-02-17
LOW DOse vs standard dose and administration TIme in near-infrared fluorescence cholangiography during laparoscopic cholecystectomy: a rando… Recruiting

2025-522535-33-00 Symptomatic Cholelithiasis 6 2026-02-13
Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting

2024-514400-14-00 liver transplanted patients with advanced hepatocellula 4 2026-01-23
Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy. Recruiting

2023-507106-13-00 Locally advanced rectal cancer 1 2026-01-12
The purpose of this study is to determine whether Tislelizumab, when given as a subcutaneous (SC) injection, reaches the same drug levels in… Recruiting

2025-522862-58-00 Locally advanced unresectable or metastatic gastric or 5 2026-01-09
Angiotensin II for more effective radioembolization in liver cancer: the RADIANT study Recruiting

2025-521870-33-00 Liver cancer (primary or secondary) 4 2026-01-05
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Recruiting

2024-513330-38-00 Healthy volunteers : Healthy adults with no history of 4 2026-01-02
Tolerance of local administration of cryopreserved autologous stromal vascular fraction combined with micrograft for the treatment of refrac… Recruiting

2024-519740-32-00 Crohn's disease 4 2025-12-29
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting

2024-513008-32-00 Adenocarcinoma of the gastroesophageal junction 4 2025-12-17
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
MOVE-IT Recruiting

2024-517123-39-00 crohns disease 6 2025-12-15
NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophag… Recruiting

2024-519993-38-00 resectable esophagogastric adenocarcinoma 3 2025-12-12
Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gast… Recruiting

2025-521358-41-00 CLDN18.2 positive gastro-esophageal adenocarcinoma 4 2025-12-11
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe … Recruiting

2025-522585-72-00 ulcerative colitis 6 2025-12-05